^
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
CRLF2 rearrangement + JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
EPOR rearrangement
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + vincristine + methotrexate + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
vincristine + mitoxantrone + dexamethasone + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
KRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
NRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive: C3 – Early Trials
HER-2 expression
Childhood B Acute Lymphoblastic Leukemia
trastuzumab
Resistant: C3 – Early Trials
PAX5 fusion
Childhood B Acute Lymphoblastic Leukemia
nintedanib
Sensitive: C3 – Early Trials
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
SNX2-ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Resistant: C4 – Case Studies
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MK-2206
Sensitive: D – Preclinical
CD9 expression
Childhood B Acute Lymphoblastic Leukemia
AT1412
Sensitive: D – Preclinical
FOXO1 underexpression
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide
Resistant: D – Preclinical
FOXO1 underexpression
Childhood B Acute Lymphoblastic Leukemia
prednisone
Resistant: D – Preclinical
IGH-CRLF2 fusion + JAK2 R867Q
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
JAK1 S646F
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
IGH-CRLF2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
IGH-CRLF2 fusion + JAK2 GPInsR683
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
P2RY8-CRLF2 fusion + JAK2 QGinsR683
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
EBF1-PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: D – Preclinical
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
DS-M1
Sensitive: D – Preclinical